• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
Catholic Review

Catholic Review

Inspiring the Archdiocese of Baltimore

Menu
  • Home
  • News
        • Local News
        • World News
        • Vatican News
        • Obituaries
        • Featured Video
        • En Español
        • Sports News
        • Official Clergy Assignments
        • Schools News
  • Commentary
        • Contributors
          • Question Corner
          • George Weigel
          • Elizabeth Scalia
          • Michael R. Heinlein
          • Effie Caldarola
          • Guest Commentary
        • CR Columnists
          • Archbishop William E. Lori
          • Rita Buettner
          • Christopher Gunty
          • George Matysek Jr.
          • Mark Viviano
          • Father Joseph Breighner
          • Father Collin Poston
          • Robyn Barberry
          • Hanael Bianchi
          • Amen Columns
  • Entertainment
        • Events
        • Movie & Television Reviews
        • Arts & Culture
        • Books
        • Recipes
  • About Us
        • Contact Us
        • Our History
        • Meet Our Staff
        • Photos to own
        • Books/CDs/Prayer Cards
        • CR Media platforms
        • Electronic Edition
  • Advertising
  • Shop
        • Purchase Photos
        • Books/CDs/Prayer Cards
        • Magazine Subscriptions
        • Archdiocesan Directory
  • CR Radio
        • CR Radio
        • Protagonistas de Fe
  • News Tips
  • Subscribe
Mifepristone, the first medication in a chemical abortion, is prepared for a patient at Alamo Women's Clinic in Carbondale, Ill., April 20, 2023. The Justice Department and the manufacturer of an abortion drug asked the U.S. Supreme Court Sept. 8 to overturn a lower court ruling that would limit access to the drug, setting the stage for the high court to weigh in on the future of the drug's availability. (OSV News photo/Evelyn Hockstein)

Supreme Court is asked to weigh in on future of abortion pill

September 13, 2023
By Kate Scanlon
OSV News
Filed Under: Feature, News, Respect Life, Supreme Court, World News

WASHINGTON (OSV News) — The Justice Department and the manufacturer of an abortion drug asked the U.S. Supreme Court Sept. 8 to overturn a lower-court ruling that would limit access to the drug, setting the stage for the high court to weigh in on the future of the drug’s availability.

A coalition of pro-life opponents of mifepristone, the first of two drugs used in a medication or chemical abortion, previously filed suit in an effort to revoke the U.S. Food and Drug Administration’s approval of the drug, arguing the government violated its own safety standards when it first approved the drug in 2000.

However, proponents argued mifepristone poses statistically little risk to women using it for abortion early in pregnancy and claim the drug is being singled out for political reasons.

In its filing on behalf of the FDA, the Justice Department called the appeals court ruling an “unprecedented decision,” arguing its logic “would threaten to severely disrupt the pharmaceutical industry and prevent FDA from fulfilling its statutory responsibilities according to its scientific judgment.”

The filing argued the drug is safe and that “study after study” has shown “serious adverse events are exceedingly rare” when mifepristone is taken under the approved conditions. The filing added, “For many patients, mifepristone is the best method to lawfully terminate their early pregnancies.”

It stated that revoking approval of the pill “would be damaging for women and health care providers around the Nation.”

But in a statement, Erik Baptist, senior counsel for Alliance Defending Freedom, which is representing the pro-life coalition challenging mifepristone’s approval, said the FDA “has been entrusted to serve as the nation’s gatekeeper of legal drugs.”

“By repeatedly and unlawfully removing critical safeguards in the chemical abortion regimen, the FDA has failed to protect the safety of women and girls,” he said. “Two courts have now held the FDA accountable for the damage it has done to the rule of law and the harm it has caused to countless girls and women. We hope the Supreme Court does the same.”

Earlier this year, the Supreme Court blocked a lower court’s restrictions on mifepristone, leaving the abortion pill on the market while litigation proceeds. That decision froze the lower court’s ruling to stay the FDA’s approval of the drug.

The Justice Department and Danco, the pharmaceutical company that manufactures mifepristone, previously asked the Supreme Court to intervene in the case after an appeals court allowed portions of the ruling by U.S. District Judge Matthew Kacsmaryk to take effect.

In a Sept. 8 statement, Danco said it “continues to be at the forefront of this fight and is working closely with the reproductive rights community and pharmaceutical industry to support the changes made by FDA.”

Should the Supreme Court take the case, it would likely be added to its docket in its coming term.

The two-drug chemical abortion regimen is currently legal in some form in 36 states and the District of Columbia. It is permitted in 21 states, but with some additional restrictions in the remaining 15, according to data from the Guttmacher Institute, which supports abortion access.

The Catholic Church opposes abortion, teaching that all human life is sacred from conception to natural death and that society must extend support to mothers and children. Earlier this year, Bishop Michael F. Burbidge of Arlington, chairman of the U.S. Conference of Catholic Bishops’ Committee on Pro-Life Activities, denounced Biden administration’s attempts to loosen regulations around the abortion bill, saying the U.S. bishops “decry the continuing push for the destruction of innocent human lives and the loosening of vital safety standards for vulnerable women.”

A link to the Justice Department’s filing is here: https://s3.documentcloud.org/documents/23945337/usfda-et-al-v-alliance-for-hippocratic-medicine-et-al-petition.pdf.

Read More Respect Life

Pro-life groups push back after Trump tells House GOP to be ‘flexible’ on Hyde Amendment

Wyoming Supreme Court strikes down abortion laws, including abortion pill ban

Catholic governor signs historic personhood law for the unborn in Puerto Rico

2025 spans life spectrum, from abortion and family programs to immigration and death penalty

HHS proposes new regulatory actions to prohibit gender transition procedures for minors

Approximately 50 Planned Parenthood clinics closed in 2025, report says

Copyright © 2023 OSV News

Print Print

Primary Sidebar

Kate Scanlon

Click here to view all posts from this author

For the latest news delivered twice a week via email or text message, sign up to receive our free enewsletter.

| MOST POPULAR |

  • Archbishop Lori announces clergy appointments, including associate pastor and special ministry

  • Son of Catholic influencer, prayed for by thousands, dies

  • Pope Leo’s first Extraordinary Consistory: What to expect?

  • The sun rises over the ocean Today could have been the day

  • Comboni Missionary Sister Andre Rothschild, who ministered at St. Matthew, dies at 79

| Latest Local News |

Beloved pastor who endured paralysis dies at 77

Baltimore students inspired by trip to SEEK conference in Ohio

Sister Catherine Horan, S.N.D.deN., dies at 86

Shrine prepares to share Mother Seton’s ‘Revolutionary’ impact as America turns 250

Comboni Missionary Sister Andre Rothschild, who ministered at St. Matthew, dies at 79

| Latest World News |

National Eucharistic Pilgrimage is back in 2026 — with a patriotic twist and a stop in Baltimore

SEEK 2026 summons youth to draw close to Christ, discover his plan for their lives

Archdiocese of St. Louis files to dismiss abuse charges, citing state law, case precedent

Slain state trooper, beloved and mourned by Delaware Catholics, laid to rest

Church must stand for peace, human rights, says Greenland priest, as US eyes takeover

| Catholic Review Radio |

Footer

Our Vision

Real Life. Real Faith. 

Catholic Review Media communicates the Gospel and its impact on people’s lives in the Archdiocese of Baltimore and beyond.

Our Mission

Catholic Review Media provides intergenerational communications that inform, teach, inspire and engage Catholics and all of good will in the mission of Christ through diverse forms of media.

Contact

Catholic Review
320 Cathedral Street
Baltimore, MD 21201
443-524-3150
mail@CatholicReview.org

 

Social Media

  • Facebook
  • Instagram
  • Twitter
  • YouTube

Recent

  • National Eucharistic Pilgrimage is back in 2026 — with a patriotic twist and a stop in Baltimore
  • SEEK 2026 summons youth to draw close to Christ, discover his plan for their lives
  • Archdiocese of St. Louis files to dismiss abuse charges, citing state law, case precedent
  • Slain state trooper, beloved and mourned by Delaware Catholics, laid to rest
  • Church must stand for peace, human rights, says Greenland priest, as US eyes takeover
  • Beloved pastor who endured paralysis dies at 77
  • Baltimore students inspired by trip to SEEK conference in Ohio
  • Catholics should identify neither as liberal nor conservative
  • The grandparent shortage

Search

Membership

Catholic Media Assocation

Maryland-Delaware-DC Press Association

The Associated Church Press

© 2026 CATHOLIC REVIEW MEDIA, ALL RIGHTS RESERVED